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Abstract
Dengue viruses (DENVs) are mosquito-borne flaviviruses and the causative agents of den-
gue fever and dengue hemorrhagic fever. As there are four serotypes of DENV (DENV1-4),
people can be infected multiple times, each time with a new serotype. Primary infections
stimulate antibodies that mainly neutralize the serotype of infection (type-specific), whereas
secondary infections stimulate responses that cross-neutralize 2 or more serotypes. Previ-
ous studies have demonstrated that neutralizing antibodies induced by primary infections
recognize tertiary and quaternary structure epitopes on the viral envelope (E) protein that are
unique to each serotype. The goal of the current study was to determine the properties of
neutralizing antibodies induced after secondary infection with a different (heterotypic) DENV
serotypes. We evaluated whether polyclonal neutralizing antibody responses after second-
ary infections consist of distinct populations of type-specific antibodies to each serotype
encountered or a new population of broadly cross-neutralizing antibodies. We observed two
types of responses: in some individuals exposed to secondary infections, DENV neutraliza-
tion was dominated by cross-reactive antibodies, whereas in other individuals both type-spe-
cific and cross-reactive antibodies contributed to neutralization. To better understand the
origins of type-specific and cross-reactive neutralizing antibodies, we analyzed sera from
individuals with well-documented sequential infections with two DENV serotypes only. These
individuals had both type-specific and cross-reactive neutralizing antibodies to the 2 sero-
types responsible for infection and only cross-reactive neutralizing antibodies to other sero-
types. Collectively, the results demonstrate that the quality of neutralizing (and presumably
protective) antibodies are different in individuals depending on the number of previous expo-
sures to different DENV serotypes. We propose a model in which low affinity, cross-reactive
antibody secreting B-cell clones induced by primary exposure evolve during each secondary
infection to secrete higher affinity and more broadly neutralizing antibodies.
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Author summary
The four dengue virus serotypes are emerging mosquito-borne flaviviruses and the causa-
tive agents of dengue fever and dengue hemorrhagic fever/dengue shock syndrome.
Infected people develop protective immunity to the infecting serotype but remain suscep-
tible to secondary infections with new serotypes. Both antibodies and T-cells are responsi-
ble for protection against re-infection by the same serotype. The goal of the current study
was to analyze the properties of antibodies in people who have been exposed to a single or
secondary dengue virus infections. We found that people exposed to a single infection
have neutralizing antibodies that mainly bind sites that are unique to the infecting sero-
type. In contrast, secondary infections induced more complex mixtures of neutralizing
antibodies that target regions that unique to each serotype and regions that are conserved
between serotypes. Our results have implications for understanding protective responses
after natural infections as well as responses induced by dengue vaccines.
Introduction
Dengue Virus (DENV) is a mosquito-borne flavivirus and the causative agent of dengue fever
and dengue hemorrhagic fever (DHF) [1]. Several hundred million people are estimated to
acquire DENV infections each year[2]. Dengue infections can be clinically inapparent or lead
to symptoms that range from an undifferentiated fever to severe DHF and dengue shock syn-
drome (reviewed in [3, 4]).
The DENV complex consists of 4 viruses designated as serotypes (DENV1-4)[1]. Primary
infection by DENV leads to long-term protection against the serotype of infection (homolo-
gous serotype) but not other serotypes (heterologous serotypes) [5–7]. Subsequent secondary
infection with a new serotype results in serotype cross-neutralizing antibodies that correlate
with durable protection against 2 or more serotypes [5, 7]. Recent studies have defined the
properties of human antibodies responsible for serotype-specific neutralization after primary
infection [8–12]. In the present study we investigated the properties of serum neutralizing anti-
bodies produced after recovery from secondary DENV infections.
The DENV envelope (E) protein, which binds to cellular receptors and mediates viral entry
and fusion, is the main target of neutralizing and protective antibodies [13]. The ectodomain
of E protein is composed of three domains: I, II and III (EDI, EDII and EDIII)[14]. Each
DENV particle has 180 monomers of E that are organized into 90 dimers that cover the entire
surface of the virus. The E proteins are arranged with icosahedral symmetry with each asym-
metric unit containing portions of three homodimers[15]. After primary DENV infection,
people develop a mix of DENV serotype cross-reactive and type-specific antibodies. The cross-
reactive antibodies are weakly neutralizing and have been implicated in antibody dependent
enhanement of DENVs during secondary infections [8, 16–18]. The serotype-specific antibod-
ies are strongly neutralizing and, presumably, responsible for long-term protection aganst re-
infection with the same serotype. Quaternary epitopes formed after assembly of E molecules
into higher order structures required for virion assembly are major targets of type-specific
neutralizing antibodies [8–12].
Here we report on the properties of serum neutralizing antibodies in people exposed to 2 or
more DENV infections. The studies were designed to test if people exposed to secondary infec-
tions have neutralizing antibodies that mainly recognize epitopes that are conserved between
serotypes or epitopes that are unique to each serotype previously encountered. Unlike primary
DENV infections that result in predominantly serotype-specific polyclonal neutralizing
Antibody response after secondary exposures to dengue virus
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antibody responses, some people exposed to secondary infections had neutralizing antibodies
that mainly recognized epitopes conserved between serotypes, while others had antibodies that
targeted both type-specific and conserved epitopes.
Materials and methods
Ethics statement
Blood donations were obtained from individuals who had traveled to dengue-endemic regions
and experienced a primary DENV infection. These human samples were obtained with
informed consent approximately 2 to 10 years after DENV infection. All blood donations were
collected in compliance with the Institutional Review Board of the University of North Caro-
lina at Chapel Hill. Written informed consent was obtained from all subjects before participa-
tion in the study. Blood donations were obtained from individuals who had traveled to
dengue-endemic regions or people living in endemic areas. All blood donations were collected
in compliance with the Institutional Review Board of the University of North Carolina at
Chapel Hill and the University of California at Berkeley. Written informed consent was
obtained from all subjects before participation in the study.
Immune sera
Dengue traveler study. Human sera were collected from individuals who had experi-
enced a DENV infection during travel to a DENV endemic area (Table 1). All donations were
collected in compliance with the Institutional Review Board of the University of North Caro-
lina at Chapel Hill (Protocol #08–0895). Samples were classified as primary infections if they
had neutralizing antibody to only one serotype ( 1:40 Neut50 titers) or a titer that is 4-fold
higher for one DENV serotype compared to low titers to the other serotypes. Samples were
classified as secondary infections if they had Neut50 titers greater than a 1:40 dilution for two
or more DENV serotypes.
Nicaraguan Pediatric Dengue Cohort Study. The Nicaraguan Pediatric Dengue Cohort
Study is an ongoing community-based prospective study of children 2–14 years old established
in 2004 in Managua, Nicaragua [19, 20]. Participants are encouraged to present at the first sign
Table 1. Panel of naïve and late convalescent DENV-immune human sera.
Reciprocal of Neut50 Titer
Donor
ID
Location of
infection
Year of most recent
known infection
Approximate interval between
infection and sampling (years)
DENV1 DENV2 DENV3 DENV4 Sero
Status†
30 - - - <20 <20 <20 <20 Naïve
1 Sri Lanka 1996 9 50 443 70 43 Primary
DENV2
110 Kuala Lumpur 1998 10 205 1280 153 96 Primary
DENV2
0 Indian Subcontinent Unknown Many 304 630 452 105 Repeat
25 Philippines 1975 25 179 233 47 71 Repeat
27 Thailand/Cambodian
border
1981 25 878 249 218 71 Repeat
121 Philipines 1995 16 92 371 325 179 Repeat
130 French Polynesia 1989 25 674 347 86 62 Repeat
† Primary defined as reciprocal Neut50 titer greater than 40 for one serotype only or a reciprocal Neut50 titer that is at least 4-fold greater for one serotype.
Secondary defined as reciprocal Neut50 titer greater than 40 for two or more serotypes and the highest titer not 4-fold greater than the 2nd highest titer.
https://doi.org/10.1371/journal.pntd.0005554.t001
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of illness to the HCSFV, where study physicians provide medical care and screen for signs and
symptoms of dengue. Suspected dengue cases, as defined by the traditional WHO dengue case
definition (WHO Guidelines 1997) and febrile participants without other apparent origin
(undifferentiated febrile illnesses) are analyzed for DENV infection using serological, molecu-
lar and virological methods in acute-phase (days 1–5) and convalescent-phase (14–21 days
post-onset of fever) blood samples [19, 20]. Healthy annual blood samples are also collected
for serological analysis. Neut50 titers were determined in annual samples using a flow cytome-
try-based assay with reporter viral particles representing the four DENV serotypes in human
monocytic U937 cells expressing the DENV attachment factor DC-SIGN[21, 22]. The PDCS
was approved by the Institutional Review Boards of the University of California, Berkeley, and
the Nicaraguan Ministry of Health. Parents or legal guardians of all subjects provided written
informed consent, and subjects 6 years of age and older provided assent.
Virus and recombinant envelope protein
WHO reference strains, DENV1 (West Pac 74), DENV2 (S-16803), DENV3 (CH-53489) and
DENV4 (TVP-376) were used in the present study. The strains were grown in C6/36 mosquito
cells to generate infectious stocks and Vero-81 mammalian cells to generate purified antigen.
DENVs from culture media were purified by density gradient and ultracentrifugation as previ-
ously described [23]. DENV2 (NGC) purified live virion antigen was purchased from Microbix
Biosystems, Inc. (Mississauga, Ontario, Canada). DENV2 envelope protein was produced as a
soluble recombinant protein (amino acids 1–397 of S-16803) using the Bac-to-Bac Baculovirus
Expression System (Invitrogen Life Technologies) and Sf9 insect cells. The protein was puri-
fied from cell culture supernatant using an antibody column coated with 4G2, a serotype-cross
reactive mouse monoclonal that targets a conserved region on the envelope protein. Structure
of the recombinant protein was verified by ELISA using monoclonal antibodies that bind to
well-defined epitopes on all three domains of E protein.
Fluorescent Activated Cell Sorting (FACS)-based DENV neutralization
assay
DENV neutralizing activity of human immune sera was assessed using a flow cytometry-based
assay with U937 human monocytic cells stably transfected with DC-SIGN as previously
described [24]. In brief, serially diluted human sera were incubated with virus for 45 min at
37˚C followed by the addition of U937 DC-SIGN cells. Cells were incubated with virus for 2
hours at 37˚C, washed with media to remove immune sera and unbound virus and incubated
for 24 hours at 37˚C. Cells were fixed, permeabilized and stained with 2H2-Alexa Flour 488, a
mouse monoclonal that binds to DENV pre-membrane protein. Infected cells were quantified
using a Guava flow-cytometer (Milipore). Stained cells were analyzed using GraphPad Prism
version 6.00 (La Jolla California USA, www.graphpad.com) to calculate 50% neutralization
titers as previously described [25]. We determined if depletion of specific antibodies resulted
in statistically significant (P<0.05) changes in Neut50 values by comparing neutralization
curves using the Extra Sum of Squares F test (Non-linear regression: Compare function in
GraphPad Prism version 6.00). Each control and antigen depleted serum sample was tested in
a single neutralization assay in duplicate using all 4 DENV serotypes.
Detection of DENV binding antibodies
ELISAs were conducted for both confirmation of depletion and the assessment of binding
activity to all four DENV serotypes following depletion of human DENV immune sera. Plates
were coated with either 50 ng of purified DENV or 100 ng of DENV rE in carbonate buffer at
Antibody response after secondary exposures to dengue virus
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pH 9.6 for 2 hours at room temperature. The plates were blocked with Tris-buffered Saline
containing 0.05% Tween 20 with 3% Normal Goat Serum followed by an incubation with a
1:40 dilution of control or DENV depleted human sera for 1 hour at 37˚C. Alkaline phospha-
tase conjugated Goat anti-human IgG (Sigma) was added to the plates for 1 hour at 37˚C. The
plates were washed and then developed by adding p-nitrophenyl phosphate substrate. The
optical density at 405nm was recorded using a spectrophotometer.
Whole virus depletion of DENV-specific antibodies from human immune
sera
Purified DENV was absorbed onto 4.5-μm Polybead polystyrene microspheres (Polysciences,
Inc.) at a bead (ul) to ligand (ug) ratio of 5:2. Beads were washed three times with 0.1M Borate
buffer (pH 8.5) followed by an overnight incubation with purified DENV and 0.1M Borate
buffer (pH 8.5) at room temperature (RT). Control beads were incubated with an equivalent
amount of BSA. The control and virus absorbed beads were then blocked with a 10 mg/ml
BSA solution for 30 minutes at RT followed by four washes with PBS. DENV-specific antibod-
ies were depleted from human sera by incubating virus absorbed beads with human sera
diluted 1:10 in PBS for 45 minutes at 37˚C. Typically three cycles were performed to remove
dengue-specific antibodies in each serum sample. Successful depletion of DENV-specific anti-
bodies was confirmed via an ELISA with purified DENV coated plates.
Recombinant E protein depletion of DENV-specific antibodies from
immune sera
Purified DENV2 rE protein was conjugated to magnetic dynabeads M-270 Epoxy (Invitrogen
by Life Technologies) with a bead (mg) to ligand (ug) ratio of 5:1. Beads were washed three
times with 0.1M Sodium Phosphate (7.4) followed by an overnight incubation with equal vol-
umes of purified rE protein, 0.1M Borate buffer (pH 9.5) and 3M Ammonium sulfate at 37˚C.
Control beads were incubated with the equivalent amount of BSA. Control and DENV2 rE
conjugated beads were then blocked by incubating with a 10 mg/ml BSA solution followed by
four washes with PBS. DENV2 rE-specific antibodies were depleted from human sera by incu-
bating rE conjugated beads with human sera diluted 1:10 in PBS for 45 minutes at 37˚C three
times with end-over-end mixing. Successful depletion of DENV2 rE-specific antibodies was
confirmed via an ELISA with purified DENV2 rE coated plates.
Calculating the proportion of re binding neutralizing antibodies
After depletion of sera using DENV2 rE antigen, the percentage of rE binding DENV2 neutral-
izing Abs were calculated using the following formula.
% rE binding DENV2 neutralizing Abs
¼ ð1  ðNeut50 after DV2 rE deletion = ðNeut50 after control deletionÞÞ  100:
Results
To characterize neutralizing antibodies in DENV immune sera, we initially used a panel of
eight human DENV immune sera from people who had been exposed to DENV during travel
or previous residency in a dengue endemic area (Table 1). The samples were collected between
9 and 30 years of their most likely exposure to DENV. Two sera are from primary DENV2
cases while the rest are from people exposed to two or more infections. A serum sample from a
dengue naïve human donor was used as a negative control.
Antibody response after secondary exposures to dengue virus
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To determine if DENV serotype cross-reactive or type-specific antibodies were responsible
for neutralizing activity in each serum sample, we used polystyrene beads coated with purified
dengue virions to deplete different populations of antibodies from serum samples. The anti-
bodies in each serum sample were depleted using beads coated with purified DENV2 or an
equal mixture of DENV1, 3 and 4. As a control, the serum was also incubated with beads
coated with BSA. The DENV2 depletions were expected to remove DENV2 type-specific and
DENV serotype cross-reactive antibodies, while retaining any DENV1, 3 or 4 type-specific
antibodies in the sample. After depleting with DENV2, any reduction in DENV1, 3 and 4 neu-
tralizing activity in the sample was attributed to cross-reactive (heterotypic) antibodies. Simi-
larly, when serum samples were depleted with beads containing equal amounts of purified
DENV1, 3 and 4, any reduction in DENV2 neutralizing antibody was attributed to cross-reac-
tive antibodies.
Depletion of DENV binding antibodies from primary DENV2 immune
sera
Depletion of two primary DENV2-immune sera (DT001 and DT110) using beads coated with
DENV2 resulted in a reduction of binding to DENV2 as well as DENV1, 3 and 4, demonstrat-
ing removal of cross-reactive and type-specific antibodies in the sample (S1 Fig). Antibody
depletion with the homologous (serotype of infection) DENV2 antigen led to a significant
(P<0.05; Extra Sum of Squares F test to compare neutralization curves) drop in DENV2 neu-
tralization (S1 Fig). Following depletion with DENV1, 3 and 4 coated beads, ELISA confirmed
removal of cross-reactive antibodies, while still retaining DENV2 type-specific antibodies in
the sample (S1 Fig). After removal of cross-reactive antibodies, the samples retained most of
the DENV2 neutralizing activity and the neutralization titers of the control and depleted sam-
ples were not significantly different (P>0.05; Extra Sum of Squares F test to compare neutrali-
zation curves) (S1 Fig). Fig 1A and 1B). These results are in agreement with previous reports
that following primary DENV infections neutralization of the homologous serotype is mainly
mediated by type-specific antibodies [8].
Depletion of DENV binding antibodies from secondary infection DENV
immune sera
Following secondary DENV infections, individuals are, typically, protected from two or more
serotypes. We tested whether individuals exposed to secondary infections generate individual
type-specific neutralizing populations of antibodies against each serotype or a broadly neutral-
izing cross-reactive population against 2 or more serotypes. We depleted secondary infection
sera using beads coated with DENV2 or a mixture of DENV1, 3 and 4 and performed neutrali-
zation assays (S2 Fig). In some individuals DENVs were almost exclusively neutralized by
cross-reactive antibodies, while others had a mixture of cross-reactive and type-specific neu-
tralizing antibodies (Fig 1C, 1D, 1E, 1F and 1G). For example, subject DT000 had high levels
of neutralizing antibodies to all 4 serotypes (Table 1). When DENV2 binding antibodies were
depleted from the DT000 sample, there was a significant loss (P<0.05; Extra Sum of Squares
F test) of DENV2 neutralization as expected (S2 Fig). However, there was also a significant loss
(P<0.05; Extra Sum of Squares F test) of DENV1, 3 and 4 neutralization (S2 Fig) indicating
that these serotypes were neutralized by cross-reactive antibodies (Fig 1C). Reciprocal deple-
tion of DT000 immune sera with DENV1, 3 and 4 antigens resulted in a significant loss
(P<0.05; Extra Sum of Squares F test) of DENV2 neutralization, indicating that cross-reactive
antibodies were responsible for neutralization of DENV2 as well (Fig 1C and S2 Fig). Subject
Antibody response after secondary exposures to dengue virus
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Fig 1. Neutralization properties of primary and secondary infection DENV-immune human sera depleted of
DENV-specific antibodies. Polystyrene beads coated with either purified DENV2 or a mixture of purified DENV1, 3
and 4 were used to deplete DENV2 primary immune sera (DT001 and DT110) and DENV secondary infection
immune sera (DT000, DT130, DT121, DT027 and DT025) of DENV-specific antibodies. After confirming depletion of
relevant antibodies (see S1 and S2 Figs), sera was tested for neutralization of DENV1-4. A-B. Levels of type-specific
and cross-reactive neutralizing antibodies in 2 individuals exposed to primary DENV2 infections. C-G. Levels of type-
specific and cross-reactive neutralizing antibodies in individuals exposed to secondary DENV infections.
https://doi.org/10.1371/journal.pntd.0005554.g001
Antibody response after secondary exposures to dengue virus
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DT121, another subject with neutralizing antibodies to all 4 serotypes, also had a response that
was dominated by cross reactive neutralizing antibodies (Fig 1E and S2 Fig).
DT130, a subject that strongly neutralized DENV1 and 2 but not 3 and 4 (Table 1), had a
mixture of type-specific and cross-reactive neutralizing antibodies (Fig 1D). Following
removal of DENV2 binding antibodies, we observed a major loss (P<0.05; Extra Sum of
Squares F test) of DENV2 neutralization and only a partial loss of DENV1 neutralization (S2
Fig). This result indicates that both type-specific and cross reactive antibodies are responsible
for the high DENV1 neutralizing activity in this individual (Fig 1D). Reciprocal depletion with
DENV1, 3 and 4 antigens removed all the DENV2 neutralizing activity demonstrating that
cross-reactive antibodies were responsible for neutralization (Fig 1D and S2 Fig). Samples
DT025 and DT027 also exhibited a similar pattern in which both type-specific and cross-
reactive antibodies contributed to DENV neutralization (Fig 1F and 1G, and S2 Fig). Unlike
primary DENV infections that stimulate durable serotype-specific neutralizing antibody
responses, we conclude that secondary infections result in more complex mixtures of neutral-
izing antibodies that recognize serotype-specific and cross-reactive epitopes. The proportions
of these two classes of antibodies varied between individuals exposed to secondary infections.
Depletion of DENV binding antibodies from individuals exposed to a
known sequence infection with two different DENV serotypes
To better understand different patterns of type-specific and cross reactive neutralizing anti-
bodies in people exposed to secondary DENV infections, we analyzed serum samples from 3
individuals with well documented histories of two sequential infections with different sero-
types of DENV (Table 2). These samples were obtained from a long-term prospective pediatric
DENV cohort study in Nicaragua [22]. Two of the subjects had been exposed to a first DENV2
infection followed by a second DENV3 infection (Subjects 985.8 and 3428.8). One subject had
been exposed to a DENV1 infection followed by a DENV3 infection (Subject 2934.7). In sera
collected several months after the second infection, all three subjects had varying levels of neu-
tralizing antibodies to at least 3 different serotypes (Table 2).
We depleted each post-second infection sample using beads coated with the DENV sero-
type of the 1st or 2nd infection and performed neutralization assays to estimate levels of cross-
reactive and type-specific neutralizing antibodies against each DENV serotype. All three sub-
jects had a mixture of type-specific and cross-reactive neutralizing antibodies directed to the
serotypes of known 1st and 2nd infection (Fig 2 and S3 Fig). For serotypes not “seen” by the
individual, neutralization was driven by cross-reactive antibodies only (Fig 2 and S3 Fig).
Depletion of DENV recombinant E protein binding antibodies
Our previous studies with primary DENV immune sera revealed that type-specific neutralizing
antibodies mostly targeted quaternary epitopes expressed on E protein dimers or higher order
structures but not recombinant E protein (rE), which is mainly a monomer in solution[8]. We,
Table 2. Panel of Nicaragua pediatric cohort human immune sera used in the study.
Reciprocal of Neut50 Titer following
second infection
Donor ID Serotype/Year of primary infection Serotype/Year of second infection Year sample collected DENV1 DENV2 DENV3 DENV4
985.8 DENV2/2005 DENV3/2010 2011 304 1586 887 <10
2934.7 DENV1/2005 DENV3/2009 2010 85 21 154 45
3428.8 DENV2/2005 DENV3/2011 2011 105 2143 2456 467
https://doi.org/10.1371/journal.pntd.0005554.t002
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next, addressed if neutralizing antibodies induced by secondary DENV infections targeted
simple or quaternary epitopes on E protein. When convalescent immune sera from individuals
exposed to primary DENV2 infections were depleted of DENV2 rE binding antibodies, we
observed no significant loss of DENV2 neutralization (P>0.05; Extra Sum of Squares F test),
confirming the importance of quaternary structure neutralizing antibody epitopes after pri-
mary infection (Fig 3 and S4 Fig). When convalescent immune sera from individuals exposed
to secondary DENV infections (Table 1) were depleted of DENV2 rE binding antibodies and
tested for DENV neutralization, we observed a significant decrease in DENV2 neutralizing
antibody titers (P<0.05; Extra Sum of Squares F test) (Fig 3 and S5 Fig). Our results indicate
that epitopes displayed on rE protein are a major target of DENV2 neutralizing antibodies
after secondary infections but not primary DENV2 infections.
Discussion
Recently several studies have described the properties of neutralizing antibodies generated fol-
lowing primary DENV infections and the epitopes targeted by these antibodies [8–10, 18, 26].
Although primary infections stimulate both DENV serotype-specific and cross reactive bind-
ing antibodies, only the type-specific antibodies have been linked to durable neutralizing and
protective responses. These type-specific antibodies target tertiary and quaternary structure E
protein epitopes displayed on the surface of the virus [8–10, 12].
In the current study we observed that the majority of neutralizing antibodies that develop
after secondary DENV infections recognize serotype cross reactive epitopes. The cross-reactive
neutralizing antibodies bound to simple epitopes on soluble E protein as well as more complex
epitopes displayed on the intact DENV particle. Indeed, serotype cross-reactive and neutraliz-
ing human monoclonal antibodies isolated from people exposed to secondary DENV infec-
tions bind with high affinity to simple epitopes on domain II as well as quaternary epitopes
that span across two E proteins forming a single dimer [16, 27–29].
Following secondary infections, some people had a single population of DENV serotype
cross-reactive and cross-neutralizing antibodies, whereas others had a mixture of type-specific
and cross-reactive neutralizing antibodies. We suspect that subjects like DT000 and 121 who
mainly had cross-reactive neutralizing antibodies are likely to have had multiple DENV expo-
sures resulting in broad neutralization of all 4 serotypes. Subjects like DT27 and 130, who had
Fig 2. Properties of DENV neutralizing antibodies after sequential infections with two different DENV serotypes. Subjects 985.8 (A) and 3428.8
(C) experienced sequential DENV2! DENV3 infections. Subject 2934.7 (B) experienced sequential DENV1! DENV3 infections. Polystyrene beads
coated with DENV serotypes that infected each individual were used to deplete different populations of antibodies in the samples. After confirming
depletion of relevant antibodies, the sera were tested for neutralization of DENV1-4 (see S3 Fig). The graphs depict the levels of DENV serotype-specific
and cross-reactive neutralizing antibodies in each subject after the second infection.
https://doi.org/10.1371/journal.pntd.0005554.g002
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a mixture of type-specific and cross-reactive neutralizing antibodies are likely to represent peo-
ple who have been exposed to sequential infections with 2 serotypes only. Indeed, when we
tested samples from three subjects enrolled in a long-term prospective pediatric cohort study
in Nicaragua with know exposure to just two sequential DENV serotype infections, all three
subjects had a mixture of type-specific and cross reactive neutralizing antibodies to the sero-
types responsible for the first and second infections. Tsai and colleagues recently characterized
DENV neutralizing antibodies in volunteers infected with a single serotype monovalent live
attenuated DENV vaccine or sequentially infected with two monovalent DENV vaccines rep-
resenting different serotypes [30]. They also observed type-specific neutralizing antibodies in
volunteers who received the single serotype vaccine and mixture of type-specific and cross
reactive neutralizing antibodies after sequential infection with 2 different serotypes.
We propose that low affinity DENV cross reactive memory B-cells derived from primary
infections undergo antibody somatic hyper mutation and each subsequent DENV exposure
selects and expands rare affinity matured clones with greater neutralization breadth and
potency (Fig 4). This model is supported by studies comparing the avidity and neutralization
of both monoclonal antibodies and polyclonal sera from people after primary and secondary
Fig 3. People exposed to secondary DENV infections develop neutralizing antibodies that target simple
epitopes on recombinant E protein. Primary DENV2 or secondary DENV infection convalescent immune sera
depleted of rE protein binding antibodies were assessed for neutralization of DENV2. In people exposed to
secondary DENV infections, a greater proportion of DENV2 neutralizing antibodies bound to epitopes displayed on
rE protein compared to people exposed to primary DENV2 infections (Mean of 75% vs. 26%; *P<0.018 unpaired
Student t Test to compare means). The primary immune sera data are from 2 subjects analyzed in this study (see
S4 Fig) and two subjects analyzed in a previous study[8]. All the secondary infection data are from samples
analyzed for current study.
https://doi.org/10.1371/journal.pntd.0005554.g003
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DENV infections. Analysis of polyclonal human sera following DENV infections revealed that
the avidity of DENV antibodies following secondary infection was higher than that of antibod-
ies generated following a primary infection [31]. In agreement with this, studies focusing on
group-reactive MAbs derived from primary and secondary DENV infected patients found that
the group-reactive MAbs from patients with secondary infection had stronger neutralization
potencies and higher binding avidities than those derived from patients with primary infection
[29, 32, 33]. Additional studies have identified a class of broadly neutralizing human antibod-
ies produced by plasmablasts in hospitalized cases of secondary DENV infections. Structural
analysis of these broadly neutralizing antibodies in complex with rE revealed that these anti-
bodies recognize serotype invariant sites at the E dimer interface. Collectively, these studies
support the idea that low affinity, weakly neutralizing antibody clones generated followed pri-
mary DENV infections give rise to antibodies of increasing breadth and neutralization potency
with each subsequent exposure (Fig 4).
In this study we analyzed in-depth convalescent blood samples from 10 individuals exposed
to DENV infections. While the small sample size is a weakness, it is challenging to perform
antibody depletion studies on larger panels because of the complexity of the studies and the
volume of blood required. Another limitation of our study is that the infection history of some
of the study subjects was inferred by the neutralizing antibody profile and travel history, there-
fore, definite conclusions relating antibody population characteristics to the number of sec-
ondary infections cannot be made. However, three subjects with known sequences of two
DENV infections support our conclusion that sequential infections with two serotypes result
in a mixture of cross-reactive and type-specific neutralizing antibodies to serotypes responsible
for infections, while inducing cross-reactive neutralizing antibodies only to the serotypes not
Fig 4. Model of B cell maturation following sequential DENV infections. With each successive DENV infection, the ratio of serotype-specific (TS) and
cross-reactive (CR) antibodies that contribute to DENV neutralization changes. During a primary infection (DENV1 in this example), dengue-specific naïve
B cells are activated and these cells give rise to both memory B cells (MBCs) and antibody secreting long lived plasma cells (LLPCs). This primary
response is dominated MBC and LLPCs clones producing low affinity, weakly neutralizing serotype CR antibodies. The primary response also contains
rare MBC and LLPCs producing TS antibodies that strongly neutralize DENV1. Following a secondary infection with a new serotype (DENV3 in this
example), the overall DENV-specific B-cell response will be dominated by the activation and expansion of DENV1 and 3 cross-reactive MBCs induced by
the primary infection. MBCs producing CR antibodies that bind to the second infecting serotype with high affinity will be preferentially activated. These
activated cells will re-enter germinal centers and undergo further rounds of somatic hyper mutation. CR B-cells with high affinity for the second serotype
will be selectively expanded to give rise to cross-reactive MBC and LLPCs that strongly cross-neutralize multiple serotypes. In the figure this increase in
affinity and neutralization is depicted by an increase in the color gradient (light yellow to bright orange) of CR B-cells. Following a tertiary infection (DENV2
in this example), this process is secondaryed again and results in a population of CR MBCs and LLPCs that dominate the neutralizing antibody response.
While the B-cell clones producing TS strongly neutralizing antibodies are also likely to be maintained through each successive round of infection, the TS
response will account for only a small fraction of the total neutralizing response.
https://doi.org/10.1371/journal.pntd.0005554.g004
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“seen” by the host. Studies are currently in progress using additional samples from human
dengue cohort studies with well-defined infection histories to further test our model about
the roles of sequential infections and antibody somatic hypermutations in cross-protective
immunity.
Our studies show that the prior DENV immune status of an individual has a profound
effect on the quality of neutralizing antibodies that develop after an infection. These findings
are relevant to the development of live attenuated dengue vaccines that strive to provide simul-
taneous protection against all four serotypes. In DENV naïve individuals who are vaccinated
with a single dose of live attenuated DENV vaccines, protection is likely to require type-spe-
cific protective antibody responses to each serotype. In the case of tetravalent live DENV vac-
cine formulations, these responses may not be balanced towards each serotype [34, 35]. On the
other hand, DENV-immune individuals receiving a tetravalent vaccine are likely to generate
broadly neutralizing and protective responses even if individual components in the vaccine
perform poorly. Indeed, a recent live attenuated tetravalent dengue vaccine efficacy trial dem-
onstrated higher efficacy in dengue pre-immune individuals compared to DENV naïve indi-
viduals [36, 37]. Overall, it is clear that a better understanding of the antibody response
transition from primary to secondary infection is needed to understand and improve the per-
formance of dengue vaccine in the current pipeline.
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